Development of potent antibody drug conjugates against ICAM1(+) cancer cells in preclinical models of cholangiocarcinoma

As a highly lethal adenocarcinoma of the hepatobiliary system, outcomes for cholangiocarcinoma (CCA) patients remain prominently poor with a 5-year survival of <10% due to the lack of effective treatment modalities. Targeted therapeutics for CCA are limited and surgical resection of CCA frequentl...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Bing, Wang, Xinyan, Shimura, Takaya, Huang, Andrew C, Kong, Nana, Dai, Yujie, Fang, Jianmin, Guo, Peng, Ying, Jie-Er
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505223/
https://www.ncbi.nlm.nih.gov/pubmed/37717087
http://dx.doi.org/10.1038/s41698-023-00447-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505223/
https://www.ncbi.nlm.nih.gov/pubmed/37717087
http://dx.doi.org/10.1038/s41698-023-00447-z

Ejemplares similares